Patients on ovarian cancer drug require ophthalmology follow-up due to corneal toxicity
Click Here to Manage Email Alerts
CHICAGO — Patients treated with mirvetuximab require close follow-up with an ophthalmologist due to the potential for corneal toxicity, according to a study.
In a poster presented at the American Academy of Ophthalmology meeting, Filippos Vingopoulos, MD, and colleagues sought to determine how the drug might be affecting the eyes of their patients. Mirvetuximab soravtansine (Elahere, ImmunoGen) was approved in 2022 for ovarian cancer and has a black box warning for ocular toxicity, according to the poster.
Image: Adobe Stock
Vingopoulos and colleagues followed 36 eyes of 18 patients for approximately 6 months. They found that 47% of eyes had moderate to severe ocular toxicity and another 22% had mild toxicity. Additionally, 69% of eyes had mirvetuximab-associated corneal toxicity.
Twenty eyes had decreased visual acuity. Common side effects included subepithelial deposits, corneal haze and filamentous keratitis, according to the study.
Treatment with high-potency steroids, as well as dose reduction and spacing helped resolve symptoms in 80% eyes, and 65% of eyes experienced a return to baseline in visual acuity.
“Close ophthalmology follow-up is required for oncology patients on mirvetuximab, as high potency topical corticosteroids along with dose reduction or spacing might be needed to preserve or restore vision,” Vingopoulos said in a press release. “As novel promising treatments are incorporated in our anti-cancer treatment algorithms, post-market surveillance with real-world studies and close collaboration between ophthalmology and multiple other disciplines of medicine will allow for optimal care for our patients.”
Collapse
Vingopoulos F, et al. Corneal toxicity of mirvetuximab. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.
Read more about
Click Here to Manage Email Alerts